MX2023001275A - Inhibidores de raf biciclicos fusionados y metodos para su uso. - Google Patents
Inhibidores de raf biciclicos fusionados y metodos para su uso.Info
- Publication number
- MX2023001275A MX2023001275A MX2023001275A MX2023001275A MX2023001275A MX 2023001275 A MX2023001275 A MX 2023001275A MX 2023001275 A MX2023001275 A MX 2023001275A MX 2023001275 A MX2023001275 A MX 2023001275A MX 2023001275 A MX2023001275 A MX 2023001275A
- Authority
- MX
- Mexico
- Prior art keywords
- fused bicyclic
- methods
- raf inhibitors
- tautomer
- stereoisomer
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057536P | 2020-07-28 | 2020-07-28 | |
| PCT/EP2021/071212 WO2022023447A2 (en) | 2020-07-28 | 2021-07-28 | Fused bicyclic raf inhibitors and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001275A true MX2023001275A (es) | 2023-04-24 |
Family
ID=77499800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001275A MX2023001275A (es) | 2020-07-28 | 2021-07-28 | Inhibidores de raf biciclicos fusionados y metodos para su uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11858930B2 (enExample) |
| EP (1) | EP4188552A2 (enExample) |
| JP (1) | JP2023535790A (enExample) |
| KR (1) | KR20230058399A (enExample) |
| CN (1) | CN116601150A (enExample) |
| AU (1) | AU2021314955A1 (enExample) |
| BR (1) | BR112023001557A2 (enExample) |
| CA (1) | CA3187514A1 (enExample) |
| IL (1) | IL300113A (enExample) |
| MX (1) | MX2023001275A (enExample) |
| WO (1) | WO2022023447A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4188552A2 (en) | 2020-07-28 | 2023-06-07 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic raf inhibitors and methods for use thereof |
| CN116143633A (zh) * | 2022-12-30 | 2023-05-23 | 浙江巍华新材料股份有限公司 | 一种制备2,5-二氯-4-三氟甲基苯胺的方法 |
| AU2024223957A1 (en) * | 2023-02-17 | 2025-09-04 | Jazz Pharmaceuticals Ireland Limited | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932657A (en) | 1973-11-12 | 1976-01-13 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome encapsulation of chelating agents |
| GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4830858A (en) | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| JPH0617309B2 (ja) | 1985-11-29 | 1994-03-09 | 株式会社ビタミン研究所 | アドリアマイシン包埋リポソ−ム製剤 |
| DE3611229A1 (de) | 1986-04-04 | 1987-10-08 | Basf Ag | Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US5698550A (en) | 1993-06-14 | 1997-12-16 | Pfizer Inc. | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases |
| WO1995022963A1 (en) | 1994-02-28 | 1995-08-31 | Medinova Medical Consulting Gmbh | Drug targeting system, method for preparing same and its use |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| WO1996032930A1 (en) | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US8137699B2 (en) | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| AU2002331481B2 (en) | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| ES2387886T3 (es) | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1690056A (zh) | 2004-04-30 | 2005-11-02 | 北京大学 | 三个化合物及其制备方法和用途 |
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| US7968536B2 (en) * | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
| PL2797888T3 (pl) | 2011-12-31 | 2016-12-30 | Połączone związki tricykliczne jako inhibitory kinazy raf | |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| CN109503659B (zh) | 2019-01-03 | 2021-06-18 | 凯特立斯（深圳）科技有限公司 | 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用 |
| EP4188552A2 (en) | 2020-07-28 | 2023-06-07 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic raf inhibitors and methods for use thereof |
| IL300110A (en) | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of fused bicyclic raf inhibitors |
-
2021
- 2021-07-28 EP EP21759247.6A patent/EP4188552A2/en active Pending
- 2021-07-28 MX MX2023001275A patent/MX2023001275A/es unknown
- 2021-07-28 AU AU2021314955A patent/AU2021314955A1/en active Pending
- 2021-07-28 JP JP2023505743A patent/JP2023535790A/ja active Pending
- 2021-07-28 KR KR1020237006991A patent/KR20230058399A/ko active Pending
- 2021-07-28 IL IL300113A patent/IL300113A/en unknown
- 2021-07-28 WO PCT/EP2021/071212 patent/WO2022023447A2/en not_active Ceased
- 2021-07-28 CN CN202180066002.9A patent/CN116601150A/zh active Pending
- 2021-07-28 US US17/387,049 patent/US11858930B2/en active Active
- 2021-07-28 CA CA3187514A patent/CA3187514A1/en active Pending
- 2021-07-28 BR BR112023001557A patent/BR112023001557A2/pt unknown
-
2023
- 2023-11-16 US US18/511,344 patent/US12304912B2/en active Active
-
2025
- 2025-05-12 US US19/205,876 patent/US20260092063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022023447A3 (en) | 2022-03-10 |
| AU2021314955A1 (en) | 2023-03-30 |
| US12304912B2 (en) | 2025-05-20 |
| WO2022023447A2 (en) | 2022-02-03 |
| CA3187514A1 (en) | 2022-02-03 |
| US20260092063A1 (en) | 2026-04-02 |
| US20240124452A1 (en) | 2024-04-18 |
| IL300113A (en) | 2023-03-01 |
| EP4188552A2 (en) | 2023-06-07 |
| BR112023001557A2 (pt) | 2023-04-04 |
| CN116601150A (zh) | 2023-08-15 |
| JP2023535790A (ja) | 2023-08-21 |
| US11858930B2 (en) | 2024-01-02 |
| KR20230058399A (ko) | 2023-05-03 |
| US20220033398A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| CR20220354A (es) | Inhibidores de egfr | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MX2023011282A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| MX2023000333A (es) | Sales y formas de un inhibidor wee1. | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PH12020551843A1 (en) | Salts of an fgfr inhibitor | |
| PH12019502436A1 (en) | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors | |
| MX2023001275A (es) | Inhibidores de raf biciclicos fusionados y metodos para su uso. | |
| PH12021552805A1 (en) | Cdk inhibitors | |
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2023001274A (es) | Sintesis quiral de inhibidores de raf biciclicos fusionados. | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| MX2024003475A (es) | Polimorfos como inhibidores de erbb. | |
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| MX2023000382A (es) | Inmunomoduladores heterocíclicos. | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2024012267A (es) | Inhibidores de egfr | |
| EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов |